• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

    10/3/24 8:00:00 AM ET
    $FHTX
    $MRNA
    $OMGA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FHTX alert in real time by email

    CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio.

    (PRNewsfoto/Invaio Sciences)

    Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner Emeritus at McKinsey & Company, where he has advised companies in advanced industries for more than 30 years. Andonian's background in driving strategic transformations across diverse industries aligns perfectly with Invaio's mission to revolutionize agriculture by providing farmers with more natural crop protection.

    "We are thrilled to have André take on the role of Chairman. His deep understanding of global industries, strategic acumen, and passion for sustainable solutions make him the ideal leader to guide Invaio into its next phase of growth and innovation," said Ignacio Martinez, General Partner at Flagship Pioneering. "I would also like to thank Robert for his important contribution to Invaio over the last five years and look forward to our continued collaboration."

    In addition to his role at McKinsey, Andonian has also held influential positions in various industries, including serving on the boards of leading companies, foundations and educational institutions.

    "I am honored to take on the role of Chairman at Invaio Sciences," said Andonian. "The company's approach to agriculture, grounded in cutting-edge science and a deep respect for nature, is truly transformative. I look forward to working with the team to accelerate Invaio's impact on sustainable agriculture, ensuring a healthier and more productive future for farmers and consumers alike."

    As Chairman, Andonian will play a key role in guiding Invaio's strategic direction, fostering partnerships, and scaling its innovative solutions to meet the challenges of modern agriculture. His appointment reflects Invaio's continued dedication to building a leadership team with the expertise and vision to drive meaningful change in the global agricultural sector.

    About André Andonian 

    André Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering. He has over three decades of experience advising companies around the globe on a broad range of strategic, operational, and organizational topics, with a longstanding presence in the APAC region.  

    Andonian is Senior Partner Emeritus at McKinsey & Company, where he worked for 34 years, including as Senior Partner, Chairman of Japan, and Managing Partner of Korea. He also led Client Impact & Experience across Asia and was a member of McKinsey's leadership teams in Asia, Europe, and the United States, advising clients in the high-tech, industrial, automotive & assembly, aerospace, basic materials, biotech, and private equity sectors. He was a long-term member of the firm's global board and held extensive additional senior leadership roles in support of growth, people, and overall knowledge development.  Prior to joining McKinsey, Andonian worked at Masco Corporation in the US and at IBM in Austria, Spain, and the Middle East.  

    Andonian also serves as an Independent Director of the Board of ADI, Chair of the Board of Cognaize in the US, and NC Chair of AEM Holdings in Singapore. He is a member of the Advisory Board of the Sports & Health Sciences Department of the Technical University of Munich, chairs the Foundation for Armenian Science and Technology, and is a Special Advisor to the American Chamber of Commerce in Korea.  

    As a Fulbright Scholar, Andonian received an MBA at the Wharton School of the University of Pennsylvania, an MA and BA in Social & Economic Sciences as well as a BSc in Engineering, all with highest distinction, from institutions in his hometown of Vienna, Austria.  

    About Invaio

    Invaio Sciences, a Flagship Pioneering company, is a bioplatform company accelerating the leap to nature-positive agriculture. The company builds on advances in human health and digital innovation to develop biological technologies for crop health, enabling farmers to both improve yields and use more natural crop health solutions. Invaio is addressing consumer demands and unlocking radical benefits for farmers and the environment, leaving every acre better today and for generations to come. For more information, please visit www.invaio.com or follow Invaio on X (Twitter) or LinkedIn.

    About Flagship Pioneering

    Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value. To date, Flagship has deployed over $3.8 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Foghorn Therapeutics (NASDAQ:FHTX), Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Sana Biotechnology (NASDAQ:SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/invaio-sciences-appoints-andre-andonian-as-chairman-of-the-board-of-directors-302266751.html

    SOURCE Invaio Sciences

    Get the next $FHTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FHTX
    $MRNA
    $OMGA
    $SANA

    CompanyDatePrice TargetRatingAnalyst
    Foghorn Therapeutics Inc.
    $FHTX
    2/17/2026$12.00Buy
    Jefferies
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Foghorn Therapeutics Inc.
    $FHTX
    12/18/2025$11.00Buy
    BTIG Research
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Foghorn Therapeutics Inc.
    $FHTX
    11/7/2025$12.00Buy
    Guggenheim
    Sana Biotechnology Inc.
    $SANA
    9/24/2025$5.00Outperform
    Wedbush
    Foghorn Therapeutics Inc.
    $FHTX
    9/17/2025$10.00Buy
    B. Riley Securities
    More analyst ratings

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/12/24 5:46:20 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Hoge Stephen exercised 160,009 shares at a strike of $19.15 and sold $7,814,840 worth of shares (160,009 units at $48.84) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    2/25/26 4:49:00 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Maynard Ryan D

    4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    2/24/26 4:02:39 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Maynard Ryan D

    3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    2/24/26 4:01:09 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    SEC Filings

    View All

    Foghorn Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

    2/23/26 7:00:26 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Moderna Inc.

    10-K - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:02:04 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Foghorn Therapeutics with a new price target

    Jefferies resumed coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00

    2/17/26 7:49:23 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

    WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. TD Cowen 46th Annual Health Care Conference Presentation: Tuesday, March 3, 2026, at 11:10 a.m. EDTPresenter: Adri

    2/24/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sana Biotechnology to Present at March 2026 Investor Conferences

    SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Sana will present at the Cowen 46th Annual Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026.Sana will present at the Citizens Life Sciences Conference at 1:40 p.m. ET on Wednesday, March 11, 2026. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be available at the same

    2/23/26 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 5:12:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 6:00:14 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/12/24 4:52:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Financials

    Live finance-specific insights

    View All

    Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM

    8/6/25 7:00:00 AM ET
    $MCRB
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

    First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin

    1/7/25 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

    Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I

    11/7/24 6:30:00 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies. "I am delighted to welcome Ryan to Foghorn as our new CFO as we continue to advance our first-in-class pipeline," said Adrian Gottschalk, Pres

    2/23/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

    SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper

    2/17/26 9:00:00 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care